Compumedics Secures $20M in Chinese MEG Sales as Demand for Brain Imaging Tech Rises

March 21, 2025 06:57 PM AEDT | By Team Kalkine Media

Google News:

Compumedics Secures $20M in Chinese MEG Sales as Demand for Brain Imaging Tech Rises — Image source: Shutterstock

Recent News

UGREEN Debuts Nexode Retractable Series - Your Hassle-free Travel Powe...

WuXi AppTec Receives MSCI ESG AAA Leader Rating

J.D. Power Recognizes Fifth Third as No. 1 for Banking Mobile App User...

Vietnamese Users Can Link UnionPay Cards to Alipay and WeChat Pay for...

Highlights

$20M in MEG system sales achieved in China

Latest $5.7M deal signed with Hangzhou Normal University

Growing momentum signals strong future potential in global neuroimaging market

Compumedics (ASX:CMP), a leading developer of brain research technologies, has reached a major milestone with $20 million in total sales of its magnetoencephalography (MEG) systems across China. The company’s latest $5.7 million contract has been signed with Hangzhou Normal University, marking the fourth major academic institution in China to adopt its advanced MEG technology.

The new agreement follows successful installations at Tianjin Normal University, along with previous orders from prestigious institutions such as Tsinghua University and Tianjin University. These partnerships are a testament to the growing demand for advanced neuroimaging tools in China’s expanding neurosciences sector.

MEG is a cutting-edge imaging technique that records magnetic fields generated by the brain’s natural electrical activity. This allows for precise mapping of brain function and supports both academic research and clinical diagnostics. The systems are paired with Compumedics’ CURRY neuroimaging software and additional supporting technologies, which are expected to be delivered to Hangzhou in early 2026 following site preparations.

According to the company’s global neuroimaging business director, the decision by Hangzhou Normal University came after an extensive technical evaluation of available MEG systems. The outcome solidifies Compumedics' reputation as a trusted provider of high-performance neuroimaging tools within the Chinese market.

Compumedics continues to refine its flagship Orion LifeSpan MEG system, incorporating a range of enhancements including improved sensor quality, more robust software features, and greater data compatibility. These updates are aimed at increasing system reliability, accuracy, and user convenience across upcoming deployments.

With four high-profile institutions now endorsing the technology, Compumedics is poised to expand further into international markets, with a particular focus on North America. The company views this success as a strong foundation for scaling its MEG technology globally.

The momentum achieved in China underscores the company’s growing commercial footprint and highlights its long-term commitment to innovation in brain research technologies. As academic and clinical interest in MEG continues to rise, Compumedics is well-positioned to meet the increasing demand for advanced neuroimaging solutions.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.